<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1AF41753-E0EF-42D8-AFAA-1BAC05C66DA8"><gtr:id>1AF41753-E0EF-42D8-AFAA-1BAC05C66DA8</gtr:id><gtr:name>FRAXA Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1AF41753-E0EF-42D8-AFAA-1BAC05C66DA8"><gtr:id>1AF41753-E0EF-42D8-AFAA-1BAC05C66DA8</gtr:id><gtr:name>FRAXA Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C6D0044A-2CD2-4167-B90B-922AF53E361F"><gtr:id>C6D0044A-2CD2-4167-B90B-922AF53E361F</gtr:id><gtr:name>University of Kent</gtr:name><gtr:address><gtr:line1>The Registry</gtr:line1><gtr:line4>Canterbury</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT2 7NZ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DE66D8E4-79EE-4AD4-AA2F-F81B7E69ECD1"><gtr:id>DE66D8E4-79EE-4AD4-AA2F-F81B7E69ECD1</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Selwood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MC_PC_13037"><gtr:id>258A5986-E4FD-43DF-BD75-F6E474B6D0AB</gtr:id><gtr:title>Biomedical Catalyst ? Drug product production, clinical support studies, and phase 1 trial of a new MS drug</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_PC_13037</gtr:grantReference><gtr:abstractText>We have invented a new, first in class, drug for the treatment of multiple sclerosis (MS). This drug has the potential to become the standard of care for the treatment of muscle spasticity in MS with fewer and less severe side effects for patients than current drugs. In particular earlier treatment should be achievable, countering the onset of disability and allowing a normal life to be sustained for longer. This drug has now passed pre-clinical safety studies including two species 28 day toxicology.
We are now actively seeking additional funds to enable the clinical support studies, GMP manufacture, formulation, encapsulation, and phase 1 studies on this drug. The first phase 1 study will be a SAD/MAD safety study in volunteers. Part funding has already been secured from the Wellcome Trust, and UCL business. The first volunteer is expected to be dosed in Q3 2013.</gtr:abstractText><gtr:technicalSummary>We have invented a new, first in class, drug for the treatment of multiple sclerosis (MS). This drug has the potential to become the standard of care for the treatment of muscle spasticity in MS with fewer and less severe side effects for patients than current drugs. In particular earlier treatment should be achievable, countering the onset of disability and allowing a normal life to be sustained for longer. This drug has now passed pre-clinical safety studies including two species 28 day toxicology.
We are now actively seeking additional funds to enable the clinical support studies, GMP manufacture, formulation, encapsulation, and phase 1 studies on this drug. The first phase 1 study will be a SAD/MAD safety study in volunteers. Part funding has already been secured from the Wellcome Trust, and UCL business. The first volunteer is expected to be dosed in Q3 2013.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Graz</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Patch clamp studies on endothelial cell ion channel signalling.</gtr:description><gtr:id>AE622802-FBAA-4CD2-8A1D-B59139766075</gtr:id><gtr:impact>Provided pivotal data in the identification of the mode of action of our new Multiple sclerosis drug. 
This outcome later confirmed by many additional studies.
The mode of action identification was key in enabling the licensing of this drug to the Ipsen Pharmaceutical company.</gtr:impact><gtr:partnerContribution>Provided expertise in patch clamp electrophysiology on endothelial cell systems.</gtr:partnerContribution><gtr:piContribution>Supplied research tools and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Investigation of T-type calcium channel bioactivity.</gtr:description><gtr:id>5D7DA45D-76FF-4304-ADD8-E483B9EC2F1D</gtr:id><gtr:impact>Too early.</gtr:impact><gtr:partnerContribution>Investigation of T-type calcium channel bioactivity of test compounds.</gtr:partnerContribution><gtr:piContribution>Supply of research materials and expertise.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FRAXA Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Investigation of VSN16R in Fragile X syndrome models, collaboration with FRAXA</gtr:description><gtr:id>A1C5282E-57B6-4B26-8A15-27AD577A59B8</gtr:id><gtr:impact>1 Testing of one molecule in the genetic (FMRP knockout) model of fragile X.</gtr:impact><gtr:partnerContribution>FRAXA is a foundation and is solely committed to finding a cure for fragile X. FRAXA organise resources and funding including testing of candidate drugs in experimental (genetic) models of disease.</gtr:partnerContribution><gtr:piContribution>We initiated a collaboration with FRAXA (https://www.fraxa.org/ ) a foundation committed to finding treatments for Fragile X syndrome. Fragile X is the major genetic condition leading to profound learning disabilities in adults. It affects approximately 1 in 4000 males and 1 in 6000 females. We arranged testing of our candidate MS drug VSN16R in genetic models of the disease in their contracting laboratory in Santiago, Chile. The molecule showed highly promising activity giving responses in 4/5 behavioral readouts.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assays of test materials in sympathetic neurotransmission models.</gtr:description><gtr:id>4FB3E203-7A5E-4B23-A71B-1D7EE8D6CEEB</gtr:id><gtr:impact>Identification of small molecules with potent activity in this assay.</gtr:impact><gtr:partnerContribution>Assays of test materials in sympathetic neurotransmission models.</gtr:partnerContribution><gtr:piContribution>Supply of test materials and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Excitatory or inhibitory transmission at single synapses</gtr:description><gtr:id>355A960C-2CE2-43CE-9747-AA1BA9E30643</gtr:id><gtr:impact>Too early.</gtr:impact><gtr:partnerContribution>Expert electrophysiology studies on excitatory and inhibitory transmission at single synapses.</gtr:partnerContribution><gtr:piContribution>Supply of research materials and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigation of test materials on functional signalling in mesenteric arteries.</gtr:description><gtr:id>7A1C8E0F-878D-46C1-BD9B-6C2A64571203</gtr:id><gtr:impact>Too early.</gtr:impact><gtr:partnerContribution>Functional studies on potassium channel signalling in mesenteric arteries.</gtr:partnerContribution><gtr:piContribution>Supply of research materials and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kent</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Effects of test drugs on TASK currents from transiently expressed channels.</gtr:description><gtr:id>B6F540EE-0D9C-436B-A03A-42B5E545C5E8</gtr:id><gtr:impact>Too early.</gtr:impact><gtr:partnerContribution>Study of the effects of drugs on TASK currents from transiently expressed channels.</gtr:partnerContribution><gtr:piContribution>Supply of research materials and expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BLOG</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D86C45B-7EE1-4E3C-A7B9-0747BE3D5913</gtr:id><gtr:impact>There are up to 250,000 visits to the site each month and about 7,000-9,000 a day.
The audience is clinicians , basic scientists, pharmaceutical industry, charities, people with disease, regulators

We got first line drug approval for an MS drug. Did our campaign on the blog contribute, who knows?
We got clinical trials funded for a number of MS drugs. Did our campaign and post influence this, who knows? 
We champion elimination of bad laboratory practice in relation to animal experimentation in MS. Does this influence practice who knows?

Hard to tell</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://multiple-sclerosis-research.blogspot.co.uk/</gtr:url><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8A5B9D20-4A8F-4353-9311-7DC7BBEE7D9C</gtr:id><gtr:impact>Full day of interaction with people with MS and their families.

The talk has been uploaded to Youtube ejs6r95NZhA linked from our Research Website.. (http://multiple-sclerosis-research.blogspot.com/2014/09/ms-day-whats-new-in-lab.html). http://www.MS-res.org. This site for people with MS attracts 1 60,000 visits a month.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://multiple-sclerosis-research.blogspot.com/2014/09/ms-day-whats-new-in-lab.html</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>79B57C67-DD0E-4AFB-8FA4-B6000A26F1EA</gtr:id><gtr:impact>Gave a lecture in a Cafe Scientific format for the Fight for Sight charity detailing some of our work on glaucoma. This was held in the Silver Cup pub in Harpenden.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.eventbrite.co.uk/e/new-drugs-for-glaucoma-its-all-about-the-electricity-tickets-28833426555?ref=enivte001&amp;invite=MTA5NzQ2MDgvam9hbm5hQGZpZ2h0Zm9yc2lnaHQub3JnLnVrLzA%3D&amp;utm_source=eb_email&amp;utm_medium=email&amp;utm_campaign=invitemodernv2&amp;ref=enivte</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit by year 12 pupils</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E2BC9882-3BE8-4969-AB36-4390AEBC48AF</gtr:id><gtr:impact>This was an event for y12 science students at a local school in Hertfordshire (Stanborough Academy). The objective was to give the students exposure to practical methods in chemistry, biology and physics. The students crystallised a protein in the lab and then conducted an X-ray experiment to show how protein structures are determined. Feedback from this day was very positive. This event was repeated in 2017.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.stanborough.herts.sch.uk/news_and_events_post16_chemistry_day_at_ucl_jan2016_.html</gtr:url><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>551726</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>The Development Of Selective Ion Channel Activators For Neuroprotection</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>National Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>FF-1602-07939</gtr:fundingRef><gtr:id>94967EE9-C18F-455F-BF3F-7F3750D5C8F4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96096</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Detect and treat hearing loss and tinnitus</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:fundingRef>CDE100571</gtr:fundingRef><gtr:id>06F34510-E95A-4F06-85A9-B148AD09D4A2</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120165</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industry CASE studentship competition</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>92C89FBD-4BD7-4902-A67B-BAD24D6C5DC4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168765</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHARACTERISATION OF THE MECHANISM OF A POTENTIAL NEW GLAUCOMA DRUG</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:fundingRef>1858/1859</gtr:fundingRef><gtr:id>CD54224B-0A24-43A8-B4DD-01BE16430369</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Composition of matter patent for our MS drug.</gtr:description><gtr:id>B26CD0AD-CFD3-4AF1-80E7-A9BCD520BAAD</gtr:id><gtr:impact>Phase I clinical study in the UK completed.
phase II clinical study in the UK ongoing, expected to complete Q4 2016.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO05080316</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>MODULATORS OF CANNABINOID RECEPTORS</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.</gtr:description><gtr:id>263AC685-A6ED-467A-B443-436F562E984C</gtr:id><gtr:impact>None so far.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2016128772 (A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BKCa Channel activator for treating muscular disorder</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof.The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form.</gtr:description><gtr:id>2BBB1931-499A-4850-9CD1-1F4973DC5AF7</gtr:id><gtr:impact>Enabled phase I study conducted in the UK.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2014111720</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CRYSTALLINE FORM OF VSN16</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Compounds of a specified general formula for the treatment of disorders associated with BK channel modulation.</gtr:description><gtr:id>62B062C5-8DE2-48B5-9286-CE255E82CE44</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2016128771 (A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Compounds for treating disorders associated with BK channel modulation</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A composition of matter patent on new analogues with activity against spasticity. These molecules may be useful new drugs for the treatment of a wide range of conditions such as MS related spasticity, fragile X and epilepsy.</gtr:description><gtr:id>776EEF06-86FA-422B-B2F1-FF73243A56BA</gtr:id><gtr:impact>Too early.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2015082938(A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A process patent on the manufacture of our new MS drug, this patent protects the main process route and variations thereof, it is granted in Europe</gtr:description><gtr:id>FBDCC2AE-5FEE-4CA6-A723-F7B3EBBBBAD5</gtr:id><gtr:impact>Phase I trial conducted in the UK.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2010116116</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>New investigational drug for MS related spasticity. Phase II study.</gtr:description><gtr:id>8E2373F2-9300-4D78-85B7-BD734EBE214C</gtr:id><gtr:impact>Trial still ongoing. Readout expected in 2017.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>VSN16R</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02542787?term=VSN16R&amp;rank=1</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have invented a new treatment for spasticity in multiple sclerosis and have recently (June 2014) completed the phase I studies and reproductive toxicology for this drug. This drug has the potential to become the standard of care for the treatment of muscle spasticity in MS with fewer and less severe side effects for patients than current drugs. In particular earlier treatment should be achievable, countering the onset of disability and allowing a normal life to be sustained for longer. We are now actively seeking additional funds to enable the clinical proof of concept phase IIa study in MS patients. This study will be conducted in the University College Hospital (UCH), London, with first recruitment expected in 2015. This drug is now ready for a phase II clinical study. The most recent principle source of funding for this development was the TSB grant (this project submission).</gtr:description><gtr:id>4609D123-EE57-4B16-A4FC-0E011BCD014F</gtr:id><gtr:impact>Wide use of mostly UK based clinical and pre-clinical contract research organisations, direct spend of the grant money in these organisations stimulating economic activity. 
Building research expertise in UK universities. 
Building clinical expertise in the treatment of MS.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>VSN16R</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>QLON-2013-VSN16R-001</gtr:ukcrnIsctnId><gtr:url>http://www.canbex.co.uk/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have generated a new dataset of RNAseq data for the mouse model of spasticity (EAE) in multiple sclerosis. This dataset shows the changes in gene expression in going from normal to EAE mice and provides insight into the changes that can also go on in the human disease. This raw sequencing data was uploaded to the Gene Expression Omnibus (GEO) with accession number GSE78996.</gtr:description><gtr:id>245A35E0-55B6-4D98-AA93-3D7D7280C381</gtr:id><gtr:impact>The RNAseq data is rationalised and discussed in the publication.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RNAseq data for mouse model of multiple sclerosis</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78996</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have identified novel and extremely potent activators of a specific potassium channel that could prove useful as pharmacological tools and possibly as drugs. These agents have been protected by a new patent application (see IP section).</gtr:description><gtr:id>E7845633-93B6-4891-A86D-172B4DAE84C3</gtr:id><gtr:impact>This funding has enabled a Phase I trial in healthy volunteers to be completed successfully.
A phase II trial in people with MS is now underway.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Candidate drug for spasticity in Multiple Sclerosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.canbex.co.uk/</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Canbex Therapeutics Ltd</gtr:companyName><gtr:description>Canbex Therapeutics is a spin-out company from University College London. Canbex is a capital-efficient, single-asset, low-burn vehicle that was established expressly to develop the VSN compound series. In addition to its pioneering scientific founders, Canbex has assembled a highly skilled and experienced team of managers and advisors. Development activities are carried out through professionally managed outsourcing to well-established CROs and CMOs.</gtr:description><gtr:id>A9ACA5AD-057A-415A-AE44-FA7D2A1D5B6A</gtr:id><gtr:impact>Canbex is building on years of work by pioneering scientists and leading clinicians, who set out to address a medical need in multiple sclerosis that is poorly served by existing therapies. Spasticity is among the most painful, damaging and debilitating symptoms of MS. Spasticity is characterized by sudden and uncontrollable movements of limb and torso musculature. Current drug treatments have a high level of undesirable side effects, and many patients are treated with palliative measures alone, such as pads or slings, or confined to a wheelchair.
The company's lead compound VSN16R, discovered in the labs of its scientific founders, is a novel orally active small molecule compound that was designed to be substantially more tolerable than existing anti-spastic agents. In tests to date, VSN16R does not cause the flaccidity, sedation or other side-effects that are major disadvantages of other agents. A phase II study in patients is ongoing.</gtr:impact><gtr:url>http://www.canbex.co.uk/index.html</gtr:url><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81975EAA-ED61-44D3-970B-3AB79D643207"><gtr:id>81975EAA-ED61-44D3-970B-3AB79D643207</gtr:id><gtr:title>Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d85f39b6d852747621223e4f816e93a6"><gtr:id>d85f39b6d852747621223e4f816e93a6</gtr:id><gtr:otherNames>Sevastou I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7CE27DF-B936-40C7-B7DB-B78AB1475DDA"><gtr:id>E7CE27DF-B936-40C7-B7DB-B78AB1475DDA</gtr:id><gtr:title>Phosphoinositide Modulation of Heteromeric Kv1 Channels Adjusts Output of Spiral Ganglion Neurons from Hearing Mice.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35970ccf8972f54a63bd68e161ff20d3"><gtr:id>35970ccf8972f54a63bd68e161ff20d3</gtr:id><gtr:otherNames>Smith KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5173E184-35C7-4654-9387-3D57F13A7AFD"><gtr:id>5173E184-35C7-4654-9387-3D57F13A7AFD</gtr:id><gtr:title>Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis and related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ededd387eee154d33bf5a12d4e8dba02"><gtr:id>ededd387eee154d33bf5a12d4e8dba02</gtr:id><gtr:otherNames>Giovannoni G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2211-0348</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13037</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>